Health Care & Life Sciences » Biotechnology | Protalix BioTherapeutics Inc.

Protalix BioTherapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
11,513.00
15,160.00
4,364.00
9,199.00
19,242.00
34,240
Cost of Goods Sold (COGS) incl. D&A
5,428.00
9,053.00
3,100.00
8,398.00
15,231.00
9,302
Gross Income
6,085.00
6,107.00
1,264.00
801.00
4,011.00
24,938
SG&A Expense
40,698.00
38,422.00
29,798.00
39,768.00
43,700.00
46,450
EBIT
34,613.00
32,315.00
28,534.00
38,967.00
39,689.00
21,512
Unusual Expense
1,000.00
1,000.00
-
14,063.00
39,386.00
-
Non Operating Income/Expense
8,497.00
8,111.00
4,864.00
5,804.00
3,336.00
2,204
Interest Expense
674.00
4,935.00
3,735.00
10,665.00
9,725.00
7,685
Pretax Income
27,790.00
29,943.00
27,282.00
29,176.00
85,276.00
26,457
Consolidated Net Income
27,790.00
29,943.00
27,282.00
29,176.00
85,276.00
26,457
Net Income
27,790.00
29,943.00
27,282.00
29,176.00
85,276.00
26,457
Net Income After Extraordinaries
27,790.00
29,943.00
112,601.00
28,987.00
85,276.00
26,457
Net Income Available to Common
27,790.00
29,943.00
18,138.00
29,365.00
85,276.00
26,457
EPS (Basic)
0.30
0.32
0.61
0.29
0.65
0.18
Basic Shares Outstanding
92,368.10
92,891.80
94,922.40
101,387.70
131,086.00
147,135.20
EPS (Diluted)
0.30
0.32
0.61
0.29
0.65
0.18
Diluted Shares Outstanding
92,368.10
92,891.80
94,922.40
101,387.70
131,086.00
147,135.20
EBITDA
31,074.00
29,175.00
26,164.00
36,984.00
37,769.00
19,841
Non-Operating Interest Income
-
196.00
123.00
589.00
188.00
536

About Protalix BioTherapeutics

View Profile
Address
2 Snunit Street
Carmiel HZ 21614
Israel
Employees -
Website http://www.protalix.com
Updated 07/08/2019
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.